Strong India growth and M&A are expected to drive June-quarter revenues, but fading Revlimid sales, US pricing pressure and weak generic launches are likely to keep margins under strain.
Strong India growth and M&A are expected to drive June-quarter revenues, but fading Revlimid sales, US pricing pressure and weak generic launches are likely to keep margins under strain.
Share this Article
Recommended